Identification of CFHR4 as a Potential Prognosis Biomarker Associated With Immune Infiltrates in Hepatocellular Carcinoma

Hongjun Yu1,2†, Chaoqun Wang1,2†, Shanjia Ke1,2†, Miaoyu Bai1,2†, Yanan Xu1,2, Shounan Lu1,2, Zhigang Feng1,2,3, Baolin Qian1,2, Yue Xu4, Menghua Zhou1,2, Zihao Li1,2, Bing Yin1,2, Xinglong Li1,2, Yongliang Hua2,5, Yongzhi Zhou1, Shangha Pan2, Yao Fu6* and Yong Ma1,2*

1 Department of Minimal Invasive Hepatic Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China, 2 Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China, 3 The First Department of General Surgery, Affiliated Hospital of Inner Mongolia Minzu University, Tongliao, China, 4 Department of Pediatrics, Hainan Hospital of PLA General Hospital, Sanya, China, 5 Department of Pediatric Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China, 6 Department of Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Background: Complement factor H-related 4 (CFHR4) is a protein-coding gene that plays an essential role in multiple diseases. However, the prognostic value of CFHR4 in hepatocellular carcinoma (HCC) is unknown.

Methods: Using multiple databases, we investigated CFHR4 expression levels in HCC and multiple cancers. The relationship between CFHR4 expression levels and clinicopathological variables was further analyzed. Various potential biological functions and regulatory pathways of CFHR4 in HCC were identified by performing a Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and Gene Set Enrichment Analysis (GSEA). Single-sample gene set enrichment analysis (ssGSEA) was performed to confirm the correlation between CFHR4 expression and immune cell infiltration. The correlations between CFHR4 expression levels in HCC and N6-methyladenosine (m6A) modifications and the competing endogenous RNA (ceRNA) regulatory networks were confirmed in TCGA cohort.

Results: CFHR4 expression levels were significantly decreased in HCC tissues. Low CFHR4 expression in HCC tissues was significantly correlated with the patients’ sex, race, age, TNM stage, pathological stage, tumor status, residual tumor, histologic grade and alpha fetal protein (AFP) level. GO and KEGG analyses revealed that differentially expressed genes related to CFHR4 may be involved in the synaptic membrane, transmembrane transporter complex, gated channel activity, chemical carcinogenesis, retinol metabolism, calcium signaling pathway, PPAR signaling pathway, insulin and gastric acid secretion. GSEA revealed that the FCGR-activated reaction, PLK1 pathway, ATR pathway, MCM pathway, cascade reactions of PI3K and FGFR1, reactant-mediated MAPK activation and FOXM1 pathway were significantly enriched in
INTRODUCTION

HCC is the sixth most common cancer worldwide. Over 900,000 new cases of HCC are confirmed each year, and approximately 800,000 people die of HCC annually, making it the third most common cause of cancer-related death. The morbidity and mortality rates of HCC are 2 to 3 times higher in men than in women in most areas (1). In China, the death rate of HCC is the highest among men over 60 years of age. The number of new cases of liver cancer diagnosed each year accounts for approximately 50% of all cases worldwide. The key determinants of liver cancer are chronic HBV infection, aflatoxin exposure or both (1, 2). The development of surgical procedures has improved the survival rate of patients with early-phase HCC, but many patients already have advanced HCC at the diagnosis, resulting in a poor overall survival rate. Therefore, the identification of new, relevant biomarkers is urgently needed to improve the early diagnosis, prognostic assessment and treatment of HCC (3–5).

Research shows that the complement system is a vitally important component of innate immunity and is extensively involved in innate immune recognition, adaptive cell stimulation and proinflammatory effector responses. The complement system exerts a regulatory effect on the tumor microenvironment, influencing the outcome of the immune response (6, 7). The factor H/CFHR family includes five complement F factor H-related proteins (CFHR1/2/3/4/5), factor H and complement factor H-like protein (CFHL1) (8, 9). CFHRs are secreted plasma proteins synthesized mainly by hepatocytes. CFHR4 is a key component of the innate immune system, and its expression is restricted to the liver (10). To date, numerous studies have suggested a role for CFHR4 in immune system disorders, such as age-related macular degeneration (AMD) (10, 11), systemic lupus erythematosus (12) and atypical hemolytic uremic syndrome (AHUS) (13, 14). However, the association of CFHR4 with HCC has not yet been characterized.

The N6-methyladenosine (m6A) RNA and competing endogenous RNA (ceRNA) regulatory network is currently a new direction in cancer therapy, and the mechanisms have been extensively studied in HCC (15). Current studies mainly focus on methyltransferases, demethylases and binding proteins (16, 17). Although the mechanism of the m6A regulatory factor requires further study, the roles of the m6A regulatory factor in tumor proliferation, invasion and metastasis have been confirmed (18). In addition, ceRNA regulatory networks are also crucial for the emergence and development of multiple cancers, including ovarian cancer (19), esophageal cancer (20) and gastric cancer (21). However, no studies have examined the ceRNA regulatory network of CFHR4 in HCC or reported on its association with m6A regulators.

In the present study, we analyzed CFHR4 expression levels in HCC tumors and normal liver tissue from multiple datasets. An analysis of RNA sequencing (RNA-Seq) data from TCGA revealed the clinical relevance and potential diagnostic and prognostic roles of CFHR4 in HCC. In addition, we further explored the biological significance of CFHR4 by performing enrichment analyses and a protein–protein interaction (PPI) network analysis and determining the correlation with immune cell infiltration. After analyzing the correlation of CFHR4 and m6A, we constructed ceRNA regulatory networks involving CFHR4 in HCC.

MATERIALS AND METHODS

RNA-Seq Data Source
We first collected gene expression data and clinical data from 424 patients with HCC in TCGA (https://portal.gdc.cancer.gov). In addition, the RNA sequencing data (GSE14520) were downloaded from the Gene Expression Omnibus (GEO) database. HTSeq-FPKM of level 3 format was converted into transcripts per million (TPM). Screening was performed to exclude patients with incomplete information, and the TPM data from 374 patients were used in subsequent analyses (Supplementary Table 1). The evolution process used the “ggplot2” R package.

Cell Lines and Cell Culture
Normal human liver cells (WRL68) were purchased from AcceGen (Fairfield, USA), and HCC cell lines (BEL7402, SK-
hep1, HCCLM3, HepG2 and Huh7) were purchased from the Chinese Academy of Science (Shanghai, China). WRL68 cells were cultured in RPMI-1640 medium, and other cell lines were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. All cells were incubated in a 37°C incubator with 5% CO2.

**HCC Tissue Collection**

We collected 30 pairs of HCC tissues and adjacent liver tissues at the First Affiliated Hospital of Harbin Medical University from 2006 to 2013 after obtaining informed consent from patients. The research project was conducted under the supervision of the Ethics Committee of the First Affiliated Hospital of Harbin Medical University.

**Quantitative Real-Time PCR**

Quantitative real-time PCR was performed on the samples as described previously (5). The following primers were used: CFHR4-F, 5’-TGCGGTTTAAGCTCCATGACA-3’; CFHR4-R, 5’-CCCATCTTCACCAACACATATG-3’; GAPDH-F, 5’-TGA CTTCAACACGGCAACCCCA-3’ and GAPDH-R, 5’-CACCCCT GTTGCTGTAGCCAAA-3’. GAPDH was used as a control to determine changes in mRNA levels using the 2^ΔΔCT method.

**Identification of Differentially Expressed Genes**

The differentially expressed genes (DEGs) between high CFHR4 expression and low CFHR4 expression samples from TCGA database were analyzed using the DEseq2 (1.26.0) R package (22) with Student’s t test. Differences were considered statistically significant for an adjusted p value < 0.05 and absolute log2-fold change > 1.5. Moreover, volcano plots and heatmaps were constructed to visualize the DEGs.

**Gene Set Enrichment Analysis (GSEA)**

Pathway enrichment analyses were performed with the “clusterProfiler” R package (23, 24). The c2.cp.v7.2symbols.gmt curated gene sets were retrieved from the Molecular Signatures Database (MSigDB). Each analytical technique was conducted repeatedly a thousand times. An FDR-corrected q value < 0.25 and adjusted p value< 0.05 were considered statistically significant.

**ssGSEA of Immune Cell Infiltration**

We analyzed the levels of infiltration of 24 types of immune cells in HCC using the ssGSEA method with the GSVA package in R. We then quantified the enrichment score for each immune cell by performing gene expression profiling of each HCC sample based on the signature of immune cells (25, 26).

**Construction and Evaluation of the Nomogram**

The univariate Cox regression analysis of the correlation between CFHR4 expression and the values multiple clinical prognostic parameters in patients with HCC was performed using R software with the “survival” package. Using the RMS package (version 6.2-0) and survival package (version 3.2-10), nomograms including important clinical features and calibration plots were constructed.

**Prediction and Construction of ceRNA Networks**

By analyzing GTEx and TCGA datasets, we investigated the CFHR4 expression across cancer types using the Wilcoxon rank sum test, including adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney...
chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), skin cutaneous melanoma (SKCM), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), uterine corpus endometrial carcinoma (UCEC) and uterine carcinosarcoma (UCS). We found that CFHR4 expression was significantly decreased in LiHC and CHOL compared with normal tissues (Figure 1A). We obtained similar results from the Timer and GEPIA databases (Supplementary Figures 1A, B). According to the expression of CFHR4 in 374 HCC tissues and 50 normal liver tissues, we confirmed that the CFHR4 expression level was also noticeably decreased in HCC tissues (P<0.001) (Figure 1B). Furthermore, CFHR4 was underexpressed in the GSE14520 HCC cohort (P<0.001) (Figure 1C). Similar results were obtained for adjacent HCC tissues among the 50 matched HCC tissues and adjacent HCC tissues (P<0.05) (Figure 1D). We extracted protein from human normal hepatic cells (WRL68) and HCC cells (BEL7402, SK-hep1, HCCLM3, HepG2 and Huh7) and confirmed the low expression of CFHR4 in HCC cells using Western blot (Figure 1E). Subsequently, 30 pairs of HCC samples were validated, and similar conclusions were reached (Figure 1F). CFHR4 mRNA expression levels were further validated using quantitative real-time PCR analyses (P<0.001) (Figures 1G, H). In addition, we constructed the receptor operating characteristic (ROC) curve. The area under the curve (AUC) for CFHR4 was 0.698, and it has a significant diagnostic value for HCC (Figure 1I).

Identification of DEGs in HCC

According to the CFHR4 expression level, we divided the data from patients with HCC into high and low CFHR4 expression groups for comparison. The DESeq2 package was used to infer CFHR4-associated genes and analyze the DEGs between the high and low expression groups. An adjusted p value < 0.05 and absolute log2-fold change > 1.5 were considered statistically significant. A total of 721 significant DEGs were identified. 113 DEGs were associated with the high CFHR4 expression group, and 608 DEGs were associated with the low CFHR4 expression group (Figure 1J and Supplementary Table 2). The top 10 DEGs were identified, further analyzed using HTSeq-Counts and sorted by relative expression (Figure 1K).

GO and KEGG Enrichment Analyses

GO and KEGG enrichment analyses were performed using the “clusterProfiler” R package to further analyze the potential biological functions of CFHR4-related DEGs. The GO analysis indicated that CFHR4-related DEGs may be involved in gated channel activity, regulation of signal release, regulation of ion transmembrane transport, metal ion transmembrane transporter activity, synaptic membrane, transmembrane transporter complex and passive transmembrane transporter activity (Figures 2A, B; Supplementary Table 3). In the KEGG enrichment analysis, CFHR4-related DEGs were mainly involved in chemical carcinogenesis, retinol metabolism, the calcium signaling pathway, the PPAR signaling pathway, bile secretion, insulin secretion and gastric acid secretion (Figures 2C, D).

CFHR4-Related Signaling Pathways Based on GSEA

GSEA was conducted between the high and low CFHR4 expression groups to further reveal CFHR4-related signaling pathways in HCC. The following pathways were significantly enriched in patients with low CFHR4 expression: FCGR-activated reaction, PLK1 pathway, reactant FcERI-mediated MAPK activation, ATR pathway, MCM pathway, cascade reaction of PI3K and FGFR1, reactant-mediated MAPK activation and FOXM1 pathway (Figures 2E–J; Supplementary Table 4).

PPI Network Analysis

We explored the association between 721 DEGs in the HCC group using the STRING database by setting the interaction threshold to 0.70 and constructed a PPI network to further investigate the underlying mechanisms (Figure 3A; Supplementary Table 5). Subsequently, 301 proteins and 420 edges were screened, and five central gene clusters were identified using a total score ≥5000 (Figures 3B–E). In addition, the top 7 central genes were screened, including CENPA, CDC20, UBE2C, CEP55, BIRC5, FAM64A and TRIP13 (Figure 3G). By analyzing the GeneMANIA and STRING online datasets, potential CFHR4-interacting target genes were identified (Supplementary Figures 2A, B). CFHR4-related genes were selected by performing a crossover analysis, including C3, CRP, CFHR1, CFHR3 and CFHR5 (Supplementary Figure 2C). We subsequently analyzed the association between CFHR4 and the 5 intersecting genes (Supplementary Figures 2D–H).

Correlation Between CFHR4 Expression and Immune Cell Infiltration

Based on the ssGSEA algorithm, we confirmed and quantified the correlations between CFHR4 expression and the immune cell infiltration levels (Figure 4A). The expression of CFHR4 was negatively correlated with aDCs, TFH cells, NK CD56bright cells and Th2 cells, and it has positive correlations with Th17 cells, DCs, neutrophils, mast cells, Tgd cells, Tcm cells, cytotoxic cells, Tregs, NK cells, pDCs, eosinophils, iDCs, B cells, T cells, CD8 T cells, Tems, NK CD56dim cells, T helper cells, macrophages and Th1 cells (Figures 4B–H). We further confirmed the correlation between CFHR4 expression with immunomarker of various immune cells in HCC. The results showed that CFHR4 expression was significantly correlated with the immunomarkers IRF5 and INOS of M1 macrophages in HCC (Table 1). It indicated that CFHR4 may induce macrophages to M1 polarization in HCC. This analysis of immune markers of different functions T cells showed that CFHR4 expression was highly correlated with the most immunomarkers (CD8B, CD3D, STAT1, IFN-γ, STAT5A, IL21, TGFβ, PD-1, CTLA4, LAG3 and TIM-3) of T cells in HCC (Table 1). It turns out that CFHR4 may perform an indispensable role in the T cells’ immune response to HCC. Especially for T cells.
FIGURE 1 | Differences in the expression of CFHR4 and CFHR4-associated DEGs. (A) CFHR4 expression levels in different cancer tissues compared to normal tissues (TCGA). (B–D) CFHR4 expression in HCC samples. (E) CFHR4 expression was detected in WRL68, BEL7402, SK-Hep1, HCCLM3, HepG2, and Huh7 cell lines using Western blotting. (F) CFHR4 protein expression in 30 paired adjacent noncancerous tissues and HCC tissues. (G) CFHR4 expression was detected in WRL68, BEL7402, SK-Hep1, HCCLM3, HepG2, and Huh7 cell lines using PCR. (H) CFHR4 mRNA expression in 30 paired adjacent noncancerous tissues and HCC tissues. (I) ROC curves were created to investigate the value of CFHR4 in identifying HCC tissues. (J, K) Volcano plots of the DEGs and heatmap showing the top 10 DEGs. *p < 0.05, **p < 0.01, ***p < 0.001, NS, no significance.
FIGURE 2 | Functional enrichment analyses of CFHR4-related genes in HCC. (A, B) The enriched terms in GO categories in HCC. (C, D) KEGG pathway analysis based on CFHR4-associated DEGs. (E–J) GSEA enrichment plots, including FCGR, activated reaction, PLK1 pathway, reactant FCERI-mediated MAPK activation, ATR pathway, MCM pathway, cascade reactions of PI3K and FGFR1, reactant-mediated MAPK activation and FOXM1 pathway.
FIGURE 3 | PPI network enrichment analysis. (A) The PPI network was built based on PPI pairs identified by the STRING dataset. (B–F) Hub gene clusters were selected from the PPI network (criteria of total scores ≥ 5,000). (G) Top 7 hub genes in the PPI network.
exhaustion, consistent results with the GISTIC analysis were obtained. The somatic copy number alteration (SCNA) module demonstrated that the arm-level deletion of CFHR4 was markedly associated with immune cell infiltration levels in HCC (Figure 4I). In addition, the results also showed a correlation between CFHR4 expression and the immunomarkers of TAMs, neutrophils, and dendritic cells (Table 1). Subsequently, according to the expression level of CFHR4, HCC samples were dichotomized into CFHR4-high and low expression groups, we aimed to reveal whether different expression groups of CFHR4 differ in the tumor immune microenvironment of HCC (Figure 4I). We found that cytotoxic cells, DCs, iDCs, mast cells, neutrophils, NK cells, pDCs, Tcm cells, Tem cells, Tgd cells, Th17 cells and Tregs were increased in the CFHR4 high expression group (P < 0.05), while the NK CD56bright cells, TFH cells and Th2 cells decreased (P < 0.05). These findings confirmed that reduced expression of CFHR4 in HCC was closely associated with immune cell infiltration.
## TABLE 1 | Correlation analysis between CFHR4 expression and biomarkers of immune cells.

| Description             | Gene markers | LIHC |
|-------------------------|--------------|------|
| CD8+ T cell             | CD8A         | < 0.001 < 0.001 |
|                         | CD8B         | 0.205 0.206 |
| T cell (general)        | CD3D         | 0.750 0.750 |
|                         | CD3E         | 0.665 0.666 |
|                         | CD2          | 0.777 0.765 |
| B cell                  | CD19         | 0.689 0.688 |
|                         | CD79A        | 0.205 0.206 |
| Monocyte                | CD86         | < 0.001 < 0.001 |
|                         | CD115 (CSF1R) | 0.665 0.666 |
| TAM                     | COL2         | 0.006 0.006 |
|                         | CD69         | 0.205 0.206 |
|                         | IL10         | 0.006 0.006 |
| M1 Macrophage           | INOS (NOS2)  | < 0.001 < 0.001 |
|                         | IRF5         | < 0.001 < 0.001 |
| M2 Macrophage           | COX2 (PTGS2) | 0.665 0.666 |
| Neutrophils             | CD69b (CEACAM8) | < 0.001 < 0.001 |
|                         | CD11b (ITGAM) | 0.665 0.666 |
|                         | CCR7         | 0.205 0.206 |
| Natural killer cell     | KIR2DL1      | 0.205 0.206 |
|                         | KIR2DL3      | 0.205 0.206 |
|                         | KIR2DL4      | 0.205 0.206 |
|                         | KIR3DL1      | 0.205 0.206 |
|                         | KIR3DL2      | 0.205 0.206 |
|                         | KIR3DL3      | 0.205 0.206 |
|                         | KIR2DS4      | 0.205 0.206 |
|                         | HLA-DPB1     | 0.205 0.206 |
|                         | HLA-DQB1     | 0.205 0.206 |
|                         | HLA-DRA      | 0.205 0.206 |
|                         | HLA-DPA1     | 0.205 0.206 |
|                         | BDC1-1 (CD1C) | 0.205 0.206 |
| Dendritic cell          | BDC1-4 (NR1P1) | 0.205 0.206 |
|                         | CD11c (ITGAX) | 0.205 0.206 |
| Th1                     | T-bet (TBX21) | 0.205 0.206 |
|                         | STAT4        | 0.205 0.206 |
|                         | STAT1        | 0.205 0.206 |
|                         | IFN-γ (IFNG) | 0.205 0.206 |
|                         | TNF-α (TNF)  | 0.205 0.206 |
| Th2                     | GATA3        | 0.205 0.206 |
|                         | STAT6        | 0.205 0.206 |
|                         | STAT5A       | < 0.001 < 0.001 |
|                         | IL13         | 0.205 0.206 |
| Th                         | BCL6         | 0.205 0.206 |
|                         | IL21         | 0.205 0.206 |
|                         | STAT3        | 0.205 0.206 |
|                         | IL17A        | 0.205 0.206 |
| Th17                    | FOXP3        | 0.205 0.206 |
|                         | CCR8         | 0.205 0.206 |
|                         | STAT5B       | 0.205 0.206 |
|                         | TGFβ3 (TGB1) | 0.205 0.206 |
| T cell exhaustion       | PD-1 (PDCD1) | < 0.001 < 0.001 |
|                         | CTLA4        | < 0.001 < 0.001 |
|                         | LAG3         | < 0.001 < 0.001 |
|                         | TIM-3 (HAVC2R) | < 0.001 < 0.001 |
|                         | GZMB         | 0.205 0.206 |
|                         | FOXP3        | 0.205 0.206 |

The bold values indicates that the correlation analysis between CFHR4 and biomarker of immune cell is statistically significant.

## Correlation Between the CFHR4 Expression Level and Clinical Characteristics

The clinical data from patients with HCC in TCGA database were obtained to investigate the clinical characteristics of patients with different CFHR4 expression levels. After removing patients with incomplete clinical data, 374 patients remained for further analysis; the average age was 61.5 years (49.25 to 70.00 years), and 67% were male. Table 2 provides a detailed description of the clinical data. We evaluated the differences in clinicopathological variables after stratifying patients based on CFHR4 expression using the Kruskal–Wallis test, and the level of CFHR4 was strongly correlated with age, sex, race, TNM stage, histologic grade, pathological stage, tumor status, residual tumor, etc.

| Characteristic          | Low expression of CFHR4 | High expression of CFHR4 | p      |
|-------------------------|-------------------------|--------------------------|--------|
| n                       | 187                     | 187                      | 0.122  |
| Gender, n (%)           |                         |                          | 0.122  |
| Female                  | 68 (18.2%)              | 53 (14.2%)               |        |
| Male                    | 119 (31.8%)             | 134 (35.8%)              |        |
| Race, n (%)             |                         |                          | < 0.001|
| Asian                   | 100 (27.6%)             | 60 (16.6%)               |        |
| Black or African American | 6 (1.7%)               | 11 (3%)                  |        |
| White                   | 76 (21.5%)              | 107 (29.6%)              |        |
| Age, n (%)              |                         |                          | 0.011  |
| <=60                    | 101 (27.1%)             | 76 (20.4%)               |        |
| >60                     | 85 (22.8%)              | 111 (29.8%)              |        |
| T stage, n (%)          |                         |                          | 0.017  |
| T1                      | 78 (21%)                | 105 (28.3%)              |        |
| T2                      | 51 (13.7%)              | 44 (11.9%)               |        |
| T3                      | 50 (13.5%)              | 30 (8.1%)                |        |
| T4                      | 8 (2.2%)                | 5 (1.3%)                 |        |
| N stage, n (%)          |                         |                          | 0.128  |
| N0                     | 136 (52.7%)             | 118 (45.7%)              |        |
| N1                      | 4 (1.6%)                | 0 (0%)                   |        |
| M stage, n (%)          |                         |                          | 0.628  |
| M0                     | 145 (53.3%)             | 123 (45.2%)              |        |
| M1                     | 3 (1.1%)                | 1 (0.4%)                 |        |
| Pathologic stage, n (%) |                         |                          | 0.004  |
| Stage I                 | 74 (21.1%)              | 99 (28.3%)               |        |
| Stage II                | 45 (12.9%)              | 42 (12%)                 |        |
| Stage III               | 55 (15.7%)              | 30 (8.6%)                |        |
| Stage IV                | 4 (1.1%)                | 1 (0.3%)                 |        |
| Tumor status, n (%)     |                         |                          | 0.001  |
| Tumor free              | 85 (23.9%)              | 117 (33%)                |        |
| With tumor              | 92 (25.9%)              | 61 (17.2%)               |        |
| Residual tumor, n (%)   |                         |                          | 0.321  |
| R0                     | 164 (47.5%)             | 163 (47.2%)              |        |
| R1                     | 11 (3.2%)               | 6 (1.7%)                 |        |
| R2                     | 0 (0%)                  | 1 (0.3%)                 |        |
| Histologic grade, n (%) |                         |                          | < 0.001|
| G1                     | 17 (4.6%)               | 38 (10.3%)               |        |
| G2                     | 77 (20.9%)              | 101 (27.4%)              |        |
| G3                     | 80 (21.7%)              | 44 (11.9%)               |        |
| G4                     | 11 (3%)                 | 1 (0.9%)                 |        |
| AFP (ng/mL), n (%)      |                         |                          | < 0.001|
| <=400                   | 87 (31.1%)              | 128 (45.7%)              |        |
| >400                    | 46 (16.4%)              | 19 (6.8%)                |        |
vascular invasion and AFP level (Figures 5A–L). Notably, CFHR4 was expressed at higher levels in the older age group (age > 60 years) than in the younger age group (age ≤ 60 years) (P < 0.05). Significant differences in CFHR4 expression levels were also noted in different races (P < 0.001). Moreover, a higher histological grade, TNM grade, pathological stage and tumor status were also significantly associated with low CFHR4 expression. Subsequently, we further confirmed the lower CFHR4 expression level in the group with a high AFP level (>400 ng/mL) (P < 0.001). Based on these results, patients with HCC presenting lower CFHR4 expression seemed to have a more advanced tumor stage.

Prognostic Potential of CFHR4 in HCC

Afterward, we performed a series of studies to determine the association of CFHR4 expression levels with the prognosis of patients with HCC. The Kaplan–Meier Plotter analysis revealed an association between low CFHR4 expression and a poor prognosis (Figures 6A–C). Moreover, we performed subgroup analyses of OS, DSS and PFI. Patients with high CFHR4 expression had a correspondingly better prognosis for OS, DSS and PFI in the Asian group (Figures 6D–F). However, OS, DSS and PFI in the white and black or African–American subgroups were not significantly different (Supplementary Figures 3A–C). In addition, patients with HCC presenting high CFHR4 expression who were aged ≤ 60 years experienced longer OS and DSS but had a worse prognosis in terms of PFI (Figure 6G–I). However, no significant differences were observed in the younger age subgroups for OS, DSS and PFI (age ≤ 60 years) (Supplementary Figures 3D–F). We further confirmed that the T3 and T4 subgroups and the stage III and stage IV subgroups experienced poorer OS (Supplementary Figures 3G, H).

A univariate Cox regression analysis was performed with TNM stage, pathological grade, tumor status and CFHR4 expression levels to further identify factors associated with different prognoses (Supplementary Table 6). The forest plot illustrated that low expression of CFHR4 was a risk factor for the
FIGURE 6 | The prognostic value of CFHR4 in HCC. (A–C) Survival curves showing a comparison of OS, DSS and PFI between patients with HCC presenting high and low CFHR4 expression. (D–F) OS, DSS and PFI survival curves for Asian patients with HCC presenting high and low CFHR4 expression. (G–I) OS, DSS and PFI survival curves for patients with HCC aged ≤60 years presenting with high and low CFHR4 expression. (J–L) Univariate survival analysis of OS, PFI, and DSS in patients from different subgroups stratified according to TNM stage, pathological grade, tumor status, and CFHR4 expression levels. (M) For patients with HCC, a nomogram was constructed to estimate the probability of 1-, 3-, and 5-year OS. (N) Nomogram calibration plots for determining the probability of OS at 1, 3, and 5 years.
OS (Figure 6J; Supplementary Table 7), DSS (Figure 6K; Supplementary Table 6) and PFI (Figure 6L; Supplementary Table 8) of patients with HCC. According to the results of the univariate Cox regression analysis, CFHR4 expression and other independent clinicopathological factors were used to construct the point scale of the nomogram. Each variable was scored with reference to the scale of the nomogram, and the total scores were dispatched to the outcome line and predicted the prognosis of patients with at 1, 3 and 5 years. The C-index of the nomogram was 0.706 (95% confidence interval: 0.671-0.741). This result suggested that the prognostic nomogram of CFHR4 had good discriminatory power (Figure 6M). The deviation correction line in the calibration analysis approached the ideal curve, indicating that the predicted values were consistent with the observed values (Figure 6N). Consistent results were obtained with the univariate Cox regression analysis.

**CFHR4 Expression Is in Associated With m6A RNA Methylation Regulators in HCC**

As reported in previous studies, m6A RNA methylation exerts an important effect on the development of HCC (27–29). The correlations between CFHR4 expression and the expression of 23 m6A-related genes were analyzed in TCGA (Figure 7A). The correlation analysis showed significant negative correlations between the expression of CFHR4 (P < 0.05) and 15 m6A-related genes in HCC (Figures 7B–P). Furthermore, groups were established based on the median CFHR4 expression, and 211 patients were assigned to the high expression group and 210 patients were assigned to the low expression group. We determined the relationship between the CFHR4 expression level and m6A modification level in HCC by analyzing the differential expression of 23 m6A-related genes in different expression groups (Figure 7Q). The expression of YTHDC1, IGFBP1, IGFBP2, IGFBP3, YTHDF1, YTHDF2, HNRNPA2B1, LRPPRC, HNRNPC, RBMX, METTL16, METTL3, RBM15, RBM15B, VIRMA, WTAP and ALKBH5 was reduced in the high CFHR4 expression group (P < 0.05). In summary, a strong correlation was observed between m6A RNA methylation in HCC and the CFHR4 expression level.

**Construction of a CFHR4-Related ceRNA Triple Regulatory Network**

Accumulating evidence highlights the regulatory role of IncRNA–miRNA–mRNA ceRNA networks in cancers. Therefore, we analyzed and constructed a ceRNA regulatory network for CFHR4 in HCC. Through TargetScan, DIANA-microT and RNAinter database predictions, the following 11 miRNAs were jointly predicted: hsa-miR-32-3p, hsa-miR-142-5p, hsa-miR-146a-5p, hsa-miR-302c-5p, hsa-miR-361-5p, hsa-miR-4775, hsa-miR-4786-5p, hsa-miR-4795-3p, hsa-miR-5590-3p, hsa-miR-580-3p and hsa-miR-590-3p (Figure 8A). Based on the regulatory relationship in the ceRNA network, a negative correlation was observed between miRNAs and mRNAs. Four miRNAs negatively correlated with CFHR4 expression were identified and screened by performing a correlation analysis. The scatter plots showed the correlation between CFHR4 expression and the target miRNAs, and the TargetScan database was used to predict the potential binding sites in CFHR4 for target miRNAs (Figures 8B–E). Subsequently, the lncRNAs that may interact with the target miRNAs (hsa-miR-146a-5p, hsa-miR-361-5p and hsa-miR-580-3p) were further predicted using the miRNet and starBase databases (Figures 8F–H). This interaction is due to the negative correlation between the expression of lncRNAs and miRNAs. Consequently, using the starBase database, we further screened and confirmed the lncRNAs in HCC that were negatively correlated with the three target miRNAs. Based on these results, the following 10 ceRNA regulatory networks that play a role in HCC were constructed: TMEM161B-AS1-hsa-miR-146a-5p-CFHR4, CCD1C83-AS1-hsa-miR-146a-5p-CFHR4, NEAT1-hsa-miR-146a-5p-CFHR4, MALAT1-hsa-miR-146a-5p-CFHR4, XIST-hsa-miR-146a-5p-CFHR4, DNAAF4-CCPG1-hsa-miR-361-5p-CFHR4, NEAT1-hsa-miR-580-3p-CFHR4, LINC00641-hsa-miR-580-3p-CFHR4, DNAAF4-CCPG1-hsa-miR-580-3p-CFHR4 and DSAM-A51-hsa-miR-580-3p-CFHR4 (Figure 8I).

**DISCUSSION**

The CFHR family consists of five highly related proteins. Each CFHR gene has a completely duplicated structural domain in the plasma proteins, and they share high sequence identity (8, 9). Members of the CFHR family of proteins play key roles in the progression of multiple diseases through multiple mechanisms. For example, CFHR1 exacerbates atherosclerotic cardiovascular disease by altering the expression levels of C-reactive protein apolipoprotein and serum amyloid protein A (30). All CFHR genes are genetic risk factors for AMD (31). The CFHR family of genes is also important in AHUS and C3 glomerulopathy (11, 13, 32). In addition, some members of the CFHR family of proteins have been proven to exert a marked effect on the progression of a variety of cancers (33–35). However, few studies on CFHR4 have been conducted, and no studies have determined its role in cancer.

In the present study, we measured the expression level and prognostic value of CFHR4. We confirmed that CFHR4 mRNA expression was markedly downregulated in HCC and CHOL tissues, and these results were validated in multiple databases. The ROC curve analysis suggested that CFHR4 may be a promising diagnostic biomarker for differentiating HCC from normal tissue.

We confirmed the reduced expression of CFHR4 in HCC cell lines and HCC samples by performing in vitro experiments. We analyzed the DEGs related to CFHR4 to further assess the role of CFHR4 in HCC. By conducting GO and KEGG analyses, we found that differences in CFHR4 expression were significantly correlated with regulating signal release, regulation of ion transmembrane transport, gated channel activity, metal ion transmembrane transporter activity, calcium signaling pathway and the PPAR signaling pathway. Using GSEA, we also revealed that low CFHR4 expression was significantly associated with FCGR-activated reactions, the PLK1 pathway, reactant FCERI-
mediated MAPK activation, the ATR pathway, the MCM pathway, the cascade reactions of PI3K and FGFR1, reactant-mediated MAPK activation and the FOXM1 pathway in patients. PLK1 (36), MAPK (37), ATR (38), MCM (39), PI3K and FGFR1 (40) have been shown to play increasingly crucial regulatory roles in HCC, and these studies and our results indicated that CFHR4 may inhibit the development and progression of HCC by regulating these signaling pathways. However, the association of CFHR4 with these signaling pathways was first discovered here, and the regulatory mechanisms require further exploration. Furthermore, based on the DEGs, we constructed the PPI networks using the Cytoscape tool. Five central gene clusters (a total score ≥5000) and the top 7 central genes were screened, including CENPA, CDC20, UBE2C, CEP55, BIRC5, FAM64A and TRIP13. The CFHR4-interacting genes were generated using STRING and GeneMANIA online databases, and we observed five intersecting genes, including C3, CRP, CFHR1, CFHR3 and CFHR5. Existing studies have confirmed that CFHR4 regulates

**FIGURE 7** | Analysis of the association between the CFHR4 expression level and the expression of m6A-related genes in HCC. (A) Correlation of CFHR4 expression levels with m6A gene expression in HCC. (B–P) Scatter plot showing the relationship between CFHR4 and m6A genes. (Q) Correlation of m6A genes in the CFHR4 high and low expression groups of HCC tumor samples. **p < 0.01, ***p < 0.001, NS, no significance.
complement activation and opsonization on biological surfaces
by interacting with native CRP (Hebecker et al., 2010). CFHR4
interacts with C3b (C3 activation fragment) (Hellwage et al.,
1999, Hebecker and Jozsi, 2012). These conclusions promote the
credibility of the predictions from the STRING database and will
provide critical insights into the design of follow-up studies and
experimental validation.

Among the results, tumor infiltrating immune cells (TIICs)
were recently shown to play a pivotal regulatory role in tumor
progression (41). The substantial accumulation of TIICs in HCC
affects the prognosis of HCC (42). By revealing the relationship
between CFHR4 expression and the level of immune cell
infiltration in HCC, CFHR4 expression was clearly associated
with the infiltration of Th17 cells, DCs, neutrophils and Th2

**FIGURE 8** | Prediction of the ceRNA network in HCC. (A) Venn diagram showing the results for CFHR4 targets predicted using the TargetScan, DIANA-microT and RNAinter databases. (B–E) Scatter plots were generated to show miRNAs-miRNAs with significant correlations. TargetScan prediction of the potential binding sites in CFHR4 for the target miRNAs. (F–H) The lncRNAs that bind to target miRNAs were predicted using the miRNet and starBase online databases and displayed in a
Venn diagram, including hsa-miR−146−5p, hsa-miR−361−5p and hsa-miR−580−3p. (I) Sankey diagram showing the CFHR4-related ceRNA regulatory network.
cells. Th17 cells are a major effector subset of CD4+ T cells that play a vital role in host protection and autoimmune disorders (43, 44). The differentiation of Th17 cells into Th1 and Th2 cell subsets participates in regulating the response to intracellular pathogens and extracellular organisms (45). Th1/17 cells produce IFN-γ to drive antitumor immune responses (46). Multiple studies reported that increased infiltration of Th17 cells inhibits the progression of breast cancer (47). Moreover, DCs are specialized antigen-presenting cells that play important roles in the initiation and regulation of innate and adaptive immune responses (48). The antitumor effect of DCs has been confirmed (49). Neutrophils have also been proven to exert bidirectional regulatory effects on the tumor immune microenvironment (50).

Our studies indicated that high CFHR4 expression activated Th17 cells, DCs and neutrophils to promote antitumor immune responses. In addition, antigen-presenting cells might promote the polarization of CD4+ T cells toward Th1 and Th2 cell subsets. Th1 cells are mainly involved in cellular immunity and tumor clearance, and Th2 cells are involved in the stimulation of antibody production (51). Th2 cells have also been confirmed as an independent risk factor for cancer growth and progression (52, 53). The number of NK CD56bright cells is significantly increased in various cancers (54–56). Multiple studies reported that Th cells are a specialized subset of CD4+ T cells that support the germinal centers, which secrete high-affinity antibodies and provide help for memory B cells (57, 58). Additionally, Th cells were confirmed to be involved in human autoimmune responses and cancers (59, 60). Based on this information, CFHR4 modulates immune responses mediated by Th2 cells, NK CD56bright cells and Th cells in HCC. We also found that the CFHR4 CNV was significantly correlated with the levels of infiltrating CD8+ T cells, macrophages, neutrophils, and dendritic cells. In addition, CFHR4 expression is strongly correlated with various immunomarker groups in HCC. We confirmed significant correlations between CFHR4 expression and CD8+ T cells (CD8B), monocytes (CD86), TAMs (CD68 and IL10), M1 macrophages (NOS2 and IRF5), neutrophils (CD66b, CD11b, and CCR7), natural killer cells (HLA-DPβ1), dendritic cells (NRP1 and ITGAX), Th1 cells (STAT1 and IFN-γ), Th2 cells (STAT5A), Th0 cells (IL21), Th17 cells (TGFB) and exhausted T cells (PD-1, CTLA4, LG3, and TIM-3). Our identified a potentially indispensable role for CFHR4 in regulating immune cell infiltration in HCC. We explored the relationship between CFHR4 expression with OS, PFI, DSS and clinical characteristics (TNM stage, residual tumor, and histological grade) by performing univariate Cox regression analysis. Calibration plots showed good agreement between predicted values of CFHR4-related column line plots and forecasted and observed values for 1-, 3- and 5-year OS probabilities. These results were consistent with those of the univariate Cox regression analysis.

The m6A methylation exerts a substantial effect on tumor cell proliferation, invasion and migration (61). Currently, m6A RNA and ceRNA regulatory networks are widely studied to determine HCC mechanisms (15). We further analyzed the relationship between CFHR4 expression and m6A modifications and determined that CFHR4 expression had inseparable relationships with IGF2BP2, IGF2BP3, YTHDF1, HNRNPA2B1, LRPPRC, HNRNPC, RBMX, RBM15B and WTAP expression. We also observed significant correlations between high CFHR4 expression and YTHDC1, IGF2BP1, IGF2BP2, IGF2BP3, YTHDF1, YTHDF2, HNRNPA2B1, LRPPRC, HNRNPC, RBMX, METTL16, METTL3, RBM15, RBM15B, VIRMA, WTAP and ALKBH5 expression. Multiple studies have now reported that IGF2BP1 (62), IGF2BP2 (28), IGF2BP3 (63), YTHDF1 (64), YTHDF2 (29), BRMX (65), RBM15 (66), METTL3 (67) and WTAP (27) are significantly upregulated in HCC, and their overexpression promotes HCC progression and is associated with a poor prognosis for patients with HCC. These discussions further supported our results. Thus, these findings suggested that the CFHR4 gene may be modified by m6A to increase the stability of its mRNA, which further inhibits the proliferation, invasion and migration of HCC. Subsequently, we constructed ceRNA regulatory networks based on the prediction. Because the ceRNA regulatory networks of CFHR4 were derived from a bioinformatics analysis, more experiments are needed to validate this network in future studies.

Although we increased our awareness of the regulatory mechanism of CFHR4 in HCC, the study had several limitations. Initially, the expression levels of CFHR4 and the important regulatory mechanisms and pathways related to CFHR4 in HCC should be further validated and evaluated by analyzing clinical samples from more centers. Secondly, However, the potential diagnostic value of the circulating CFHR4 content in HCC patients is not clear, and the clinical significance of circulating tumor markers remains to be further explored. In addition, the relationship between CFHR4 and interacting genes and m6A genes in HCC should be further explored and validated. In future studies, we will further elucidate the potential regulatory mechanisms of CFHR4 in HCC by performing more experiments.

**CONCLUSIONS**

In summary, this study represents the first in-depth analysis of CFHR4 in HCC. Our study suggested that CFHR4 was abnormally downregulated in HCC and that its reduced expression was correlated with a poorer prognosis. We confirmed the correlation between CFHR4 expression and the m6A modification, indicating that CFHR4 may be modified by m6A to improve mRNA stability. The construction of ceRNA networks suggested that CFHR4 may be involved in multiple molecular regulatory mechanisms of HCC. More importantly, CFHR4 expression was associated with multiple immune cells and may affect HCC tumor immunity by inducing M1 macrophage polarization and altering the infiltration of exhausted T cells. These findings provide additional insights into the mechanism by which CFHR4 may represent an important independent prognostic marker for HCC. The potential molecular mechanisms and regulatory networks of CFHR4 provide a basis for follow-up studies. The study also
provides important insights into the treatment of HCC based on genomics.

DATA AVAILABILITY STATEMENT
The article/Supplementary Material contains the original contributions presented in the study. Any additional questions can be forwarded to the corresponding authors.

ETHICS STATEMENT
The Ethics Committee of the First Affiliated Hospital of Harbin Medical University provided ethical review and approval. The patients provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
HY, CW, SK, and MB made equal contributions to this article. HY, CW, and SK planned the research trials and engaged in article writing. YNX, SL, ZF, BQ, YX, and YF attended in information generation and analysis. MZ, ZL, BY, XL, YH, YZ, and SP also provided assistance with analysis. All authors made great efforts to the article and agreed to the version submitted.

FUNDING
This work was supported by the Research Fund of the National Natural Scientific Foundation of China (81100305, 81470876 and 81270527), Natural Science Foundation of Heilongjiang Province of China (QC2013C094, LC2018037), Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province (CXPJJH11900001-2019349), Outstanding Youth Training Fund from Academician Yu Weihan of Harbin Medical University (2014), and the First Affiliated Hospital of Harbin Medical University (2019L01, HYD2020JQ0007).

REFERENCES
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3332/caac.21660
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer Statistics in China, 2015. CA Cancer J Clin (2016) 66(2):115–32. doi: 10.3332/ caac.21338
3. Forner A, Reig M, Bruix J. Hepatocellular Carcinoma. Lancet (2018) 391(10127):1301–14. doi: 10.1016/S0140-6736(18)30010-2
4. Singhal AG, Lampertico P, Nahon P. Epidemiology and Surveillance for Hepatocellular Carcinoma: New Trends. J Hepatol (2020) 72(2):250–61. doi: 10.1016/j.jhep.2019.08.025
5. Wang C, Dong L, Li X, Li Y, Zhang B, Wu H, et al. The PGC1alpha/NRF1-MPCI Axis Suppresses Tumor Progression and Enhances the Sensitivity to Sorafenib/Doxorubicin Treatment in Hepatocellular Carcinoma. Free Radic Biol Med (2021) 163:141–52. doi: 10.1016/j.freeradbiomed.2020.11.035
6. Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in Cancer: Untangling an Intricate Relationship. Nat Rev Immunol (2018) 18(1):5–18. doi: 10.1038/nri.2017.97
7. Yarmoska SK, Alawieh AM, Tomlinson S, Hoang KB. Modulation of the Complement System by Neoplastic Disease of the Central Nervous System. Front Immunol (2021) 12:689435. doi: 10.3389/fimmu.2021.689435
8. Poppelaars F, Goicoechea de Jorge E, Jongers I, Baeunner AJ, Steiner MS, Jozzi M, et al. A Family Affair: Addressing the Challenges of Factor H and the Related Proteins. Front Immunol (2021) 12:660194. doi: 10.3389/fimmu.2021.660194
9. Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement Factor H Related Proteins (CFHRs). Mol Immunol (2013) 56(3):170–80. doi: 10.1016/j.molimm.2013.06.001
10. Lores-Motta L, Paun CC, Corominas J, Pauper M, Geerlings MJ, Altay L, et al. Genome-Wide Association Study Reveals Variants in CFH and CFHR4.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.892750/full#supplementary-material

Supplementary Figure 1 | CFHR4 expression levels in different cancer tissues compared to normal tissues. (A) CFHR4 expression levels in different cancer tissues compared to normal tissues in the Timer database. (B) CFHR4 expression levels in different cancer tissues compared to normal tissues in the GEPIA database.

Supplementary Figure 2 | PPI network and potential CFHR4-interacting target genes. (A) PPI networks were built using the STRING database. (B) PPI networks were built using the GeneMANIA database. (C) The intersecting genes identified by the STRING and GeneMANIA online databases are displayed in a Venn diagram. (D) Scatter plot showing the correlation between CFHR1 and CFHR4 expression. (E) Scatter plot showing the correlation between CFHR3 and CFHR4 expression. (F) Scatter plot showing the correlation between CFHRS and CFHR4 expression. (G) Scatter plot showing the correlation between C3 and CFHR4 expression. (H) Scatter plot showing the correlation between CRP and CFHR4 expression.

Supplementary Figure 3 | The prognostic value of CFHR4 in HCC. (A–C) OS, DSS and PFI survival curves for white, black or African–American patients with HCC presenting high and low CFHR4 expression. (D–F) OS, DSS and PFI survival curves for patients with HCC aged > 60 years presenting with high and low CFHR4 expression. (G) OS curves for patients with stage T3 and T4 HCC presenting with high and low CFHR4 expression. (H) OS curves for patients with pathological stage III and IV HCC presenting with high and low CFHR4 expression.

Supplementary Table 1 | Characteristics of patients with HCC in TCGA.
Supplementary Table 2 | CFHR4-related DEGs.
Supplementary Table 3 | GO enrichment analysis of CFHR4.
Supplementary Table 4 | GSEA enrichment analysis of CFHR4.
Supplementary Table 5 | PPI network of CFHR4.
Supplementary Table 6 | OS of patients with HCC based on prognostic covariates.
Supplementary Table 7 | DSS patients with HCC based on prognostic covariates.
Supplementary Table 8 | PFI of patients with HCC based on prognostic covariates.
Associated With Systemic Complement Activation: Implications in Age-Related Macular Degeneration. *Ophthalmology* (2018) 125(7):1064–74. doi: 10.1016/j.ophtha.2017.12.023.

11. Cipriani V, Loes-Motta L, He F, Fathalla D, Takaravina V, McHarg S, et al. Increased Circulating Levels of Factor H-Related Protein 4 Are Strongly Associated With Age-Related Macular Degeneration. *Nat Commun* (2020) 11 (1):778. doi: 10.1038/s41467-020-14499-3.

12. Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, et al. Association of Genetic Variants in Complement Factor H and Factor H-Related Genes With Systemic Lupus Erythematosus Susceptibility. *PLoS Genet* (2011) 7(5):e1001207. doi: 10.1371/journal.pgen.1001207.

13. Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. *J Am Soc Nephrol* (2020) 31 (2):241–56. doi: 10.1681/ASN.2019050515.

14. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of Factor H Autoantibodies With Deletions of CFHR1, CFHR3, CFHR4, and With Mutations in CFH, CFI, CD46, and C3 in Patients With Atypical Hemolytic Uremic Syndrome. *Blood* (2010) 115(2):379–87. doi: 10.1182/blood-2009-05-221549.

15. Wang P, Wang X, Zheng L, Zhuang C. Gene Signatures and Prognostic Values of M6a Regulators in Hepatocellular Carcinoma. *Front Genet* (2020) 11:501186. doi: 10.3389/fgene.2020.501186.

16. Yang Y, Heu B, Chen YS, Yang VG. Dynamic Transcriptional M6A Decoration: Writers, Erasers, Readers and Functions in RNA Metabolism. *Cell Res* (2018) 28(6):616–24. doi: 10.1038/s41422-018-0040-6.

17. Zaccara S, Ries MJ, Jaffrey SR. Reading, Writing and Erasing mRNA Methylation. *Nat Rev Mol Cell Biol* (2021) 22(10):608–24. doi: 10.1038/s41580-019-0168-5.

18. Pan Y, Xiao K, Li Y, Li Y, Liu Q. RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma. *Front Oncol* (2021) 11:632934. doi: 10.3389/fonc.2021.632934.

19. Zhang F, Luo BH, Wu QH, Li QL, Yang KD. lncRNA HCG18 Upregulates TRAF4/TRAF5 to Facilitate Proliferation, Migration and EMT of Epithelial Ovarian Cancer by Targeting miR-29a/B. *Mol Med* (2022) 28(1):1. doi: 10.1007/s41580-021-01445-6.

20. Xue ST, Zheng B, Cao SQ, Ding JC, Hu GS, Liu W, et al. Long non-Coding RNA LINCO0680 Functions as a ceRNA to Promote Esophageal Squamous Cell Carcinoma Progression Through the miR-423-5p/PAK6 Axis. *Mol Cancer* (2022) 21(1):69. doi: 10.1186/s12943-022-01539-3.

21. Li D, Xu M, Wang Z, Huang P, Huang C, Chen Z, et al. The EMT-Induced lncRNA NR2F2-AS1 Positively Modulates NR2F2 Expression and Drives Gastric Cancer via miR-29a-3p/VAMP7 Axis. *Cell Death Dis* (2022) 13(1):841. doi: 10.1038/s41419-022-04540-2.

22. Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2. *Genome Biol* (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8.

23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles. *Proc Natl Acad Sci USA* (2005) 102(43):15454–50. doi: 10.1073/pnas.0506850102.

24. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: An R Package for Comparing Biological Themes Among Gene Clusters. *OMICS* (2012) 16(5):284–7. doi: 10.1089/omi.2011.0118.

25. Hanelmann S, Castelo R, Guinney J, GSVa: Gene Set Variation Analysis for Microarray and RNA-Seq Data. *BMC Bioinf* (2013) 14:7. doi: 10.1186/1471-2105-14-7.

26. Bindea G, Mlecnik B, Tosolini M, Kirillovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal Dynamics of Intrautram Cell Immune Cells Reveal the Immune Landscape in Human Cancer. *Immunity* (2013) 39(4):782–95. doi: 10.1016/j.immuni.2013.06.003.

27. Chen Y, Peng C, Chen J, Chen D, Yang B, He B, et al. WTPF Accomplishes Progression of Hepatocellular Carcinoma via M6a-HuR-Dependent Epigenetic Silencing of ETS1. *Mol Cancer* (2019) 18(1):127. doi: 10.1186/s12943-019-1053-8.

28. Pu J, Wang J, Qin Z, Wang A, Zhang Y, Wu X, et al. IGFB2BP2 Promotes Liver Cancer Growth Through an M6a-FEN1-Dependent Mechanism. *Front Oncol* (2020) 10:578816. doi: 10.3389/fonc.2020.578816.
Yu et al.

47. Karpisheh V, Ahmadi M, Abbaszadeh-Goudarzi K, Mohammadpour Saray M, Barshidi A, Mohammadi H, et al. The Role of Th17 Cells in the Pathogenesis and Treatment of Breast Cancer. Cancer Cell Int (2022) 22 (1):108. doi: 10.1186/s12935-022-02528-8

48. Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic Cells in Cancer Immunology and Immunotherapy. Nat Rev Immunol (2020) 20(1):7–24. doi: 10.1038/s41577-019-0210-z

49. Martinek J, Wu TC, Cadena D, Banchereau J, Palucka K. Interplay Between Dendritic Cells and Cancer Cells. Int Rev Cell Mol Biol (2019) 348:179–215. doi: 10.1016/bs.ircmb.2019.07.008

50. Shaul ME, Fridlender ZG. Neutrophils as Active Regulators of the Immune System in the Tumor Microenvironment. J Leukoc Biol (2017) 102(2):343–9. doi: 10.1189/jlb.1216-508R

51. Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al. Engineering Immune Cells. Trends Immunol (2022) 43(4):309–14. doi: 10.1016/bs.ircmb.2019.07.008

52. Orecchioni M, Bedognetti D, Newman L, Fuoco C, Spada F, Hendrickx W, et al. Single-Cell Mass Cytometry and Transcriptome Profiling Reveal the Impact of Graphene on Human Immune Cells. Nat Commun (2017) 8 (1):1109. doi: 10.1038/s41467-017-01015-3

53. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour Immunity: Effector Response to Tumour and Role of the Microenvironment. Lancet (2008) 371(9614):771–83. doi: 10.1016/S0140-6736(08)60241-X

54. Tonetti CR, de Souza-Araujo CN, Yoshida A, da Silva RF, Alves PCM, Mazzola TN, et al. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells. Cells (2021) 10(7):1702. doi: 10.3390/cells10071702

55. Nie Y, Liu D, Yang W, Li Z, Zhang L, Cheng X, et al. Increased Expression of TIGIT and KLRG1 Correlates With Impaired CD56(bright) NK Cell Immunity in HPV16-Related Cervical Intraepithelial Neoplasia. Virol J (2022) 19(1):68. doi: 10.1186/s12985-022-01776-4

56. Duan J, Lv G, Zhu N, Chen X, Shao Y, Liu Y, et al. Multidimensional Profiling Depicts Infiltrating Immune Cell Heterogeneity in the Tumor Microenvironment of Stage IA Non-Small Cell Lung Cancer. Thoric Cancer (2022) 13(7):947–55. doi: 10.1111/1759-7714.14329

57. Chen Z, Wang N, Yao Y, Yu D. Context-Dependent Regulation of Follicular Helper T Cell Survival. Trends Immunol (2022) 43(4):309–21. doi: 10.1016/j.it.2022.02.002

58. Walker LSK. The Link Between Circulating Follicular Helper T Cells and Autoimmunity. Nat Rev Immunol (2022) 21:1–9. doi: 10.1038/s41577-022-00693-5

59. Galdiero MR, Varricchi G, Marone G. The Immune Network in Thyroid Cancer. Oncoiimmunology (2016) 5(6):e1168556. doi: 10.1080/2162402X.2016.1168556

60. Bian J, Lin J, Long L, Yang X, Yang X, Lu X, et al. T Lymphocytes in Hepatocellular Carcinoma Immune Microenvironment: Insights Into Human Immunology and Immunotherapy. Am J Cancer Res (2020) 10(12):4585–606.

61. Chen H, Gao S, Liu W, Wong CC, Wu J, Wu J, et al. RNA N(6)-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the M(6)A-GLUT1-Mtorc1 Axis and Is a Therapeutic Target. Gastroenterology (2021) 160(4):1284–300.e16. doi: 10.1053/j.gastro.2020.11.013

62. Zhang J, Hu K, Yang YQ, Wang Y, Zheng YF, Jin Y, et al. LIN28B-AS1-IGF2BP1 Binding Promotes Hepatocellular Carcinoma Cell Progression. Cell Death Dis (2020) 11(9):741. doi: 10.1038/s41419-020-02967-z

63. Jiang W, Cheng X, Wang T, Song X, Zheng Y, Wang L. LINCO0467 Promotes Cell Proliferation and Metastasis by Binding With IGF2BP3 to Enhance the mRNA Stability of TRAF5 in Hepatocellular Carcinoma. J Gene Med (2020) 22(3):e3134. doi: 10.1002/jgm.3134

64. Su T, Huang M, Liao J, Lin S, Yu P, Yang J, et al. Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism. Hepatology (2021) 74(3):1339–56. doi: 10.1002/hep.31766

65. Song Y, He S, Ma X, Zhang M, Zhuang J, Wang G, et al. RBMX Contributes to Hepatocellular Carcinoma Progression and Sorafenib Resistance by Specifically Binding and Stabilizing BLACAT1. Am J Cancer Res (2020) 10 (11):3644–65.

66. Cai X, Chen Y, Man D, Yang B, Feng X, Zhang D, et al. RBM15 Promotes Hepatocellular Carcinoma Progression by Regulating N6-Methyladenosine Modification of YES1 mRNA in an IGF2BP1-Dependent Manner. Cell Death Discov (2021) 7(1):315. doi: 10.1038/s41420-021-00703-w

67. Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, et al. RNA N6-Methyladenosine Methyltransferase-Like 3 Promotes Liver Cancer Progression Through YTHDF2-Dependent Posttranscriptional Silencing of SOCS2. Hepatology (2018) 67(6):2254–70. doi: 10.1002/hep.29683

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yu, Wang, Ke, Bai, Xu, Lu, Feng, Qian, Xu, Zhou, Li, Yin, Li, Hua, Zhou, Pan, Fu and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.